Compare Kinder Morgan Inc (KMI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Novo Nordisk A/S — how do they compare? Kinder Morgan Inc trades at $32.21 (market cap $72.48B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 3× Kinder Morgan Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| KMI | NVO | |
|---|---|---|
Market Cap | $72.48B | $220.53B |
Sector | Energy | Health |
52-Week High | $34.31 | $71.70 |
52-Week Low | $25.84 | $35.29 |
Enterprise Value | $104.36B | $239.49B |
Dividend Yield | 3.61% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $32.71, up 1.27% with neutral technical signals. The company shows strong fundamentals with revenue growth from $15.1B in 2024 to $16.9B in 2025 and net income margin improving to 18.04%. Recent Q1 2026 earnings beat expectations with $0.48 EPS versus $0.40 expected. KMI maintains a $10.1B project backlog focused on natural gas infrastructure, supporting future growth. Analyst sentiment is mixed with 47% buy ratings but technical indicators show neutral momentum near key support at $32.
KMI presents a balanced opportunity with stable cash flows from fee-based contracts and dividend yield near 4%. Upside potential exists from LNG export growth and power demand, though valuation appears fair at P/E of 21.7. Key risks include commodity price exposure and high debt levels at $29.7B long-term. The stock offers income stability but limited near-term catalysts given neutral technical positioning.
Novo Nordisk (NVO) trades at $49.68, down 1.27% on the day, amid a bullish technical signal from moving averages. The company demonstrates robust fundamentals with a trailing P/E of 12.08 and a net income margin of 37.2%, supported by three consecutive quarterly earnings beats. Recent positive catalysts include EU and Indian regulatory approvals for its oral Wegovy weight-loss pill, expanding its GLP-1 franchise.
The outlook remains positive given strong analyst consensus (57.9% Buy ratings) and projected earnings growth, though risks include intensifying competition in the weight-loss drug market and potential margin pressure. The stock presents a compelling opportunity for investors seeking exposure to a profitable leader in metabolic diseases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
